Dong Kwon Kim

9PUBLICATIONS
46CO-AUTHORS
ChemotherapyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCancer geneticsGene expression (incl. microarray and other genome-wide approaches)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|May 15, 2026
Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma.

|Apr 20, 2026
A Phase II Study of Stereotactic Ablative Radiotherapy plus Atezolizumab plus Tiragolumab in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer.

|Dec 05, 2024
Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab.

Dong Kwon Kim, Chun-Bong Synn, Wongeun Lee

|Nov 28, 2024
Mutation-Driven Immune Microenvironments in Non-Small Cell Lung Cancer: Unrevealing Patterns through Cluster Analysis.

Youngtaek Kim, Joon Yeon Hwang, Kwangmin Na

|Aug 28, 2024
Exploring the Expression and Function of T Cell Surface Markers Identified through Cellular Indexing of Transcriptomes and Epitopes by Sequencing.

Joon Yeon Hwang, Youngtaek Kim, Kwangmin Na

|Jun 25, 2024
Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma.

Sun M Lim, Seong-San Kang, Dong K Kim

Pageof 2

Frequent Collaborators

7 joint publications

Kyoung-Ho Pyo

6 joint publications

Min Hee Hong

5 joint publications

Byoung Chul Cho

5 joint publications

Youngtaek Kim